Universal cell therapy trial aims to tame rogue immune system in devastating neurological diseases
NCT ID NCT07392528
Summary
This early-phase study is testing a new 'off-the-shelf' cell therapy for people with severe neurological autoimmune diseases that have not responded to other treatments. Up to 15 participants with conditions like multiple sclerosis or myasthenia gravis will receive a single infusion of specially engineered immune cells designed to target and reset the faulty immune system. The main goals are to see if the treatment is safe and to look for early signs that it can reduce disease activity and disability.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Huanhu Hospital
Tianjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.